Glaxo cutting 200-plus jobs in Romania; Novo not into the whole 'big merger' thing;

GlaxoSmithKlineBuilding

@FiercePharma: Top-read on FP this weekend: Roche and Cipla are ordered to mediate in a new twist on Indian IP fights.Story | Follow @FiercePharma

@TracyStaton: Trending now @FiercePharma: Novo Nordisk lays out plans to recruit 6,000 workers in R&D, production. Story | Follow @TracyStaton

@EricPFierce: In Allergan and Valeant takeover fight, silence is Goldman. More | Follow @EricPFierce

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

@CarlyHFierce: ICYMI--NYT: Goldman Sachs caught in the middle of Valeant, Allergan takeover fight. Article | Follow @CarlyHFierce

@JustinHFierce: PetVivo ($PETV) updates study on Kush medical device to treat animal osteoarthritis with Gel-Del, CEO Lai: "Mobility." Release | Follow @JustinHFierce

> Could Pfizer nab AstraZeneca with pipeline-based payouts? Maybe, but cash is easier. Story

> Sources: Bayer, J&J's Xarelto faces first U.S. lawsuits. More

> GlaxoSmithKline ($GSK) will close a plant in Romania, taking 236 jobs with it by 2015. Report

>Novo Nordisk ($NVO) says it sees 'no strategic reason' for big mergers. Story (sub. req.)

> Sanofi ($SNY) and Medtronic ($MDT) have announced a strategic alliance in diabetes. Release

> A Novartis ($NVS) facility in Holly Springs, NC, has become the U.S.' first pandemic-ready site licensed by the FDA to produce cell-culture flu vaccines. Release

> New study data shows that Lundbeck's Brintellix improved cognitive function in adult patients with major depression. Report

> Former Glaxo unit Convergence Pharmaceuticals is considering an IPO to raise at least £50 million ($85 million). More

Medical Device News

@FierceMedDev: Chrono Therapeutics snares $32M in Series A money for wearable smoking cessation device. More | Follow @FierceMedDev

@StacyALawrence: Mobile medical app brings laboratory testing to the home. Story | Follow @StacyALawrence

@MichaelGFierce: UCSB study: New silver nanoparticles dissolve if they don't hit their mark. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: C.R. Bard wins unanimous FDA panel vote for drug-eluting balloon catheter. Article | Follow @EmilyWFierce

> Obesity device before FDA panel despite not meeting primary endpoints. More

> $90M later, Apollo rebrands Lap-Band and hopes to best Allergan's efforts. Article

> iWatch to unite Apple healthcare strategy? Item

Biotech News

@FierceBiotech: What's next in diabetes drugs? The pulse of R&D at ADA14. More | Follow @FierceBiotech

@JohnCFierce: Vertex down about 8% now as this Porges note rattles investors. Story | Follow @JohnCFierce

@DamianFierce: Check out FierceBiotech's full 2014 ADA coverage here. | Follow @DamianFierce

> Once-monthly MS drug from Biogen Idec, AbbVie clears Phase III hurdle. More

> Boehringer, Lilly creep up on Sanofi with Lantus biosimilar. Story

> Sanofi's Lantus heir beats its forebear in controlling diabetes. Article

CRO News

> InVentiv, Oncobiologics kick off their biosimilar alliance, target Humira. More

> Karyopharm taps CRO Veristat for cancer R&D. Story

> Quintiles signs an expansive deal to chart effects of physical therapy. Article

> Korean pharma booster recruits Novotech to boost local R&D. Report

> After a year of dealmaking, PRA settles in with a new identity. News

Biotech IT News

> EMA backtracks on clinical trial data download ban. News

> Illumina working to turn smartphones into 'molecular stethoscopes.' More

> Google inks deal with Autism Speaks, commits to housing 10,000 whole genomes. Article

> Pfizer strikes tech-enabled drug discovery deal with X-Chem. Story

> AstraZeneca sponsors diabetes patient registry. More

And Finally... Aspirin may no longer be considered the best drug for preventing strokes in people with atrial fibrillation. More

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.